Tempest Therapeutics, Inc. Restructuring Costs
Tempest Therapeutics, Inc. (TPST) reported Restructuring Costs of $6.90 million for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2017-05-09
- Tempest Therapeutics, Inc. restructuring costs for the quarter ending 2017-03-31 was $6.90M.
| Period end | Restructuring Costs 3 month |
|---|---|
| 2017-03-31 | $6.90M 10-Q · filed 2017-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |